Innes Andrew J, Apperley Jane F
Centre for Haematology, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
Centre for Haematology, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK; Department of Clinical Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
Hematol Oncol Clin North Am. 2014 Dec;28(6):1037-53. doi: 10.1016/j.hoc.2014.08.002. Epub 2014 Oct 5.
Allogeneic hematopoietic stem cell transplantation (HSCT) revolutionized the outlook for many patients with chronic myeloid leukemia (CML) in the 1980s. The introduction of the tyrosine kinase inhibitors (TKIs) nearly 15 years ago displaced HSCT as the first-line treatment for most CML patients. However, in the twenty-first century HSCT remains a viable treatment option for many patients with CML. This review focuses on the role of HSCT for CML in the TKI era, paying particular attention to patient selection and transplant outcome.
异基因造血干细胞移植（HSCT）在20世纪80年代彻底改变了许多慢性髓性白血病（CML）患者的预后。近15年前酪氨酸激酶抑制剂（TKIs）的问世取代了HSCT，成为大多数CML患者的一线治疗方法。然而，在21世纪，HSCT仍然是许多CML患者可行的治疗选择。本综述重点关注HSCT在TKI时代对CML的作用，尤其关注患者选择和移植结果。
